secwatch / observer
8-K filed May 11, 2023, 7:59 PM ET ticker CDT CIK 0001896212
M&A confidence high sentiment neutral materiality 0.60

Murphy Canyon Acquisition Corp. amends merger agreement with Conduit Pharmaceuticals, extends outside date to Feb 2024

CDT Equity Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CDT Equity Inc. amended Second Amendment to the Merger Agreement with Conduit Pharmaceuticals Limited valued at Amendment to Merger Agreement to extend outside date and modify closing conditions. (effective 2023-05-11).

Action
amendment
Agreement
merger
Counterparty
Conduit Pharmaceuticals Limited
Value
Amendment to Merger Agreement to extend outside date and modify closing conditions.
Effective
2023-05-11
Exact text from the filing
On May 11, 2023, the Company, Conduit, and Merger Sub entered into a Second Amendment to the Merger Agreement (the “Second Merger Amendment” and, together with the Original Merger Agreement and the First Merger Amendment, the “Merger Agreement”) to provide for (i) removal of the provision that indicates that no tax opinion would be delivered in connection with the closing of the Conduit Business Combination, (ii) a closing obligation that that the Company either (a) be exempt from the provisions of Rule 419 promulgated under the Securities Act of 1933, as amended, other than through its net tangible assets or (b) have at least $5,000,001 of net tangible assets either immediately prior to or upon consummation of the Conduit Business Combination, and (iii) the extension of the outside date for the closing of the Conduit Business Combination from May 31, 2023, to February 7, 2024.
View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

CDT Equity Inc. filing history →

Source: SEC EDGAR
accession 0001493152-23-016403
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.